Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion

BACKGROUND Dystrophin is a large essential protein of skeletal and heart muscle. It is a filamentous scaffolding protein with numerous binding domains. Mutations in the DMD gene, which encodes dystrophin, mostly result in the deletion of one or several exons and cause Duchenne (DMD) and Becker (BMD) muscular dystrophies. The most common DMD mutations are frameshift mutations resulting in an absence of dystrophin from tissues. In-frame DMD mutations are less frequent and result in a protein with partial wild-type dystrophin function. The aim of this study was to highlight structural and functional modifications of dystrophin caused by in-frame mutations. METHODS AND RESULTS We developed a dedicated database for dystrophin, the eDystrophin database. It contains 209 different non frame-shifting mutations found in 945 patients from a French cohort and previous studies. Bioinformatics tools provide models of the three-dimensional structure of the protein at deletion sites, making it possible to determine whether the mutated protein retains the typical filamentous structure of dystrophin. An analysis of the structure of mutated dystrophin molecules showed that hybrid repeats were reconstituted at the deletion site in some cases. These hybrid repeats harbored the typical triple coiled-coil structure of native repeats, which may be correlated with better function in muscle cells. CONCLUSION This new database focuses on the dystrophin protein and its modification due to in-frame deletions in BMD patients. The observation of hybrid repeat reconstitution in some cases provides insight into phenotype-genotype correlations in dystrophin diseases and possible strategies for gene therapy. The eDystrophin database is freely available: http://edystrophin.genouest.org/.

[1]  B. Paul Morgan,et al.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome , 2007, Proceedings of the National Academy of Sciences.

[2]  N. Bresolin,et al.  Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. , 1994, Brain : a journal of neurology.

[3]  S. Winder,et al.  ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. , 2007, The Biochemical journal.

[4]  A. Fischer,et al.  Primary immunodeficiencies: 2009 update. , 2009, The Journal of allergy and clinical immunology.

[5]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[6]  H. Ochs,et al.  The role of complement in the induction of antibody responses. , 1983, Clinical and experimental immunology.

[7]  J. Mendell,et al.  Mutation rates in the dystrophin gene: A hotspot of mutation at a CpG dinucleotide , 2005, Human mutation.

[8]  M. López-Trascasa,et al.  Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. , 2009, Blood.

[9]  Peer Bork,et al.  SMART 6: recent updates and new developments , 2008, Nucleic Acids Res..

[10]  W. King,et al.  Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. , 1993, Human molecular genetics.

[11]  A. Monaco,et al.  Distal transcript of the dystrophin gene initiated from an alternative first exon and encoding a 75-kDa protein widely distributed in nonmuscle tissues. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Blom,et al.  Complement factor I in health and disease. , 2011, Molecular immunology.

[13]  N. Hattori,et al.  Undetectable dystrophin can still result in a relatively benign phenotype of dystrophinopathy , 1999, Neuromuscular Disorders.

[14]  Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database , 2012, Orphanet Journal of Rare Diseases.

[15]  A. Lupas Coiled coils: new structures and new functions. , 1996, Trends in biochemical sciences.

[16]  W. Fridman,et al.  Complement Mutation‐Associated De Novo Thrombotic Microangiopathy Following Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  L. Kunkel,et al.  An alternative dystrophin transcript specific to peripheral nerve , 1993, Nature Genetics.

[18]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[19]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[20]  Manfred J. Sippl,et al.  Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..

[21]  Andrew P. Weir,et al.  Function and genetics of dystrophin and dystrophin-related proteins in muscle. , 2002, Physiological reviews.

[22]  K. Buetow,et al.  Mapping of the human complement factor I gene to 4q25. , 1989, Genomics.

[23]  Yang Zhang,et al.  I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.

[24]  S. Winder,et al.  Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. , 2006, Trends in cell biology.

[25]  S. Pandya,et al.  Mutation Analysis in a Population-Based Cohort of Boys With Duchenne or Becker Muscular Dystrophy , 2009, Journal of child neurology.

[26]  L. Morandi,et al.  Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype , 1995, Journal of the Neurological Sciences.

[27]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[28]  M. Bobrow,et al.  Dystrophins in vertebrates and invertebrates. , 1998, Human molecular genetics.

[29]  U. Rother A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. , 1982, Journal of immunological methods.

[30]  M. López-Trascasa,et al.  Molecular characterization of Complement Factor I deficiency in two Spanish families. , 2008, Molecular immunology.

[31]  M. Sippl Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.

[32]  P. Sánchez-Corral,et al.  Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome , 2010, British journal of haematology.

[33]  F. Salvatore,et al.  Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. , 2005, Annals of human genetics.

[34]  Xin Huang,et al.  Structure of a WW domain containing fragment of dystrophin in complex with β-dystroglycan , 2000, Nature Structural Biology.

[35]  C. Licht,et al.  Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis , 2009, Thrombosis and Haemostasis.

[36]  G. van Ommen,et al.  Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.

[37]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[38]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[39]  W. Fridman,et al.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[40]  A. Monaco,et al.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein , 1988, Cell.

[41]  J. Burgunder,et al.  Becker muscular dystrophy with marked divergence between clinical and molecular genetic findings: case series. , 2006, Swiss medical weekly.

[42]  C. Gilissen,et al.  Dystrophin Gene Mutation Location and the Risk of Cognitive Impairment in Duchenne Muscular Dystrophy , 2010, PloS one.

[43]  N. Menhart Hybrid spectrin type repeats produced by exon-skipping in dystrophin. , 2006, Biochimica et biophysica acta.

[44]  M. Kirschfink,et al.  Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family , 2006, Clinical and experimental immunology.

[45]  J. T. Dunnen,et al.  Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort , 2005, American journal of medical genetics. Part A.

[46]  Andrea O'Neill,et al.  Specific interaction of the actin-binding domain of dystrophin with intermediate filaments containing keratin 19. , 2005, Molecular biology of the cell.

[47]  Anna Carla Turconi,et al.  Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up , 2011, Journal of Neurology.

[48]  D. Eisenberg,et al.  A method to identify protein sequences that fold into a known three-dimensional structure. , 1991, Science.

[49]  M. Oppermann,et al.  Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  J. T. Dunnen,et al.  Copy number variation in the genome; the human DMD gene as an example , 2006, Cytogenetic and Genome Research.

[51]  A. Blom,et al.  Genetic, molecular and functional analyses of complement factor I deficiency , 2009, European journal of immunology.

[52]  D. Fearon Purification of C3b inactivator and demonstration of its two polypeptide chain structure. , 1977, Journal of immunology.

[53]  Christophe Béroud,et al.  Genotype–phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD–DMD database: a model of nationwide knowledgebase , 2009, Human mutation.

[54]  I. Fokkema,et al.  LOVD: Easy creation of a locus‐specific sequence variation database using an “LSDB‐in‐a‐box” approach , 2005, Human mutation.

[55]  T. Partridge,et al.  Optimizing exon skipping therapies for DMD. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[56]  L. Kunkel,et al.  Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. , 1995, Human molecular genetics.

[57]  H Sugita,et al.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.

[58]  D. Parry,et al.  Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure. , 2008, Journal of structural biology.

[59]  M. Thambyayah,et al.  Prevalence and incidence of Becker muscular dystrophy , 1991, The Lancet.

[60]  K. Bushby,et al.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. , 2011, Brain : a journal of neurology.

[61]  V. Bennett,et al.  An Ankyrin-Based Mechanism for Functional Organization of Dystrophin and Dystroglycan , 2008, Cell.

[62]  L. Kunkel,et al.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.

[63]  O. Horaitis,et al.  Human Genome Variation Society , 2006, Springer Reference Medizin.

[64]  N. Plant,et al.  Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[65]  Thierry Soussi,et al.  UMD (Universal Mutation Database): 2005 update , 2005, Human mutation.

[66]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[67]  L. Ségalat Dystrophin and functionally related proteins in the nematode Caenorhabditis elegans , 2002, Neuromuscular Disorders.

[68]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[69]  P. Ray,et al.  A novel dystrophin isoform is required for normal retinal electrophysiology. , 1995, Human molecular genetics.

[70]  S. Thiel,et al.  Disease-causing mutations in genes of the complement system. , 2011, American journal of human genetics.

[71]  L. Kunkel,et al.  Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[72]  H. Zeitz,et al.  Complement factor I deficiency with recurrent aseptic meningitis. , 1993, Archives of internal medicine.

[73]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[74]  E. Bertini,et al.  Transcriptional behavior of DMD gene duplications in DMD/BMD males , 2009, Human mutation.

[75]  R. Dwek,et al.  Human complement factor I glycosylation: structural and functional characterisation of the N-linked oligosaccharides. , 2006, Biochimica et biophysica acta.

[76]  K. Davies,et al.  ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. , 2004, Human molecular genetics.

[77]  M. Saraste,et al.  Structural comparisons of calponin homology domains: implications for actin binding. , 1998, Structure.

[78]  J. Ervasti,et al.  A Cluster of Basic Repeats in the Dystrophin Rod Domain Binds F-actin through an Electrostatic Interaction* , 1998, The Journal of Biological Chemistry.

[79]  H. Ochs,et al.  Primary immunodeficiency diseases : a molecular and genetic approach , 2013 .

[80]  F. Leturcq,et al.  Clinical Heterogeneity of Duchenne Muscular Dystrophy (DMD): Definition of Sub-Phenotypes and Predictive Criteria by Long-Term Follow-Up , 2009, PloS one.

[81]  V. Frémeaux-Bacchi,et al.  Atypical hemolytic uremic syndrome , 2011, Orphanet journal of rare diseases.

[82]  F. Rivier,et al.  Mutation spectrum leading to an attenuated phenotype in dystrophinopathies , 2005, European Journal of Human Genetics.

[83]  O. Delalande,et al.  Computational Study of the Human Dystrophin Repeats: Interaction Properties and Molecular Dynamics , 2011, PloS one.

[84]  H. Sweeney,et al.  Dystrophin protects the sarcolemma from stresses developed during muscle contraction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[86]  Bernard Dan,et al.  Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.

[87]  J. Chamberlain,et al.  Interactions between dystrophin and the sarcolemma membrane. , 1997, Society of General Physiologists series.

[88]  Narmada Thanki,et al.  CDD: specific functional annotation with the Conserved Domain Database , 2008, Nucleic Acids Res..

[89]  Thomas W Prior,et al.  Experience and strategy for the molecular testing of Duchenne muscular dystrophy. , 2005, The Journal of molecular diagnostics : JMD.

[90]  B. Nilsson,et al.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). , 2008, Molecular immunology.

[91]  S. Hardy,et al.  Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. , 2009, Journal of molecular biology.

[92]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[93]  T. Gibson,et al.  Dystrophin and utrophin: the missing links! , 1995, FEBS letters.

[94]  P. Roversi,et al.  Structural basis for complement factor I control and its disease-associated sequence polymorphisms , 2011, Proceedings of the National Academy of Sciences.

[95]  Francesco Saverio Tedesco,et al.  Complement in human diseases: Lessons from complement deficiencies. , 2009, Molecular immunology.

[96]  W. Fridman,et al.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome , 2004, Journal of Medical Genetics.

[97]  Y. Hayashi,et al.  The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b. , 2010, Biochemical and biophysical research communications.

[98]  G. Puca,et al.  Novel small mutations along the DMD/BMD gene associated with different phenotypes. , 1994, Human molecular genetics.

[99]  G. Bruns,et al.  Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4. , 1987, The Journal of biological chemistry.

[100]  D. Duan,et al.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. , 2009, The Journal of clinical investigation.

[101]  J. Fajkus,et al.  Novel dystrophin mutations revealed by analysis of dystrophin mRNA: alternative splicing suppresses the phenotypic effect of a nonsense mutation , 2001, Neuromuscular Disorders.

[102]  K. Campbell,et al.  Association of dystrophin and an integral membrane glycoprotein , 1989, Nature.

[103]  F. Gudat,et al.  Glomerulonephritis in a patient with complement factor I deficiency. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[104]  A. Pestronk,et al.  Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy , 2009, Circulation. Cardiovascular genetics.

[105]  Y. Shoenfeld,et al.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation , 1998, Immunologic research.

[106]  L. Isaac,et al.  Molecular characterization of homozygous hereditary factor I deficiency , 2003, Clinical and experimental immunology.

[107]  S. Winder,et al.  Dystrophin: more than just the sum of its parts. , 2010, Biochimica et biophysica acta.

[108]  M. Walport,et al.  The molecular basis of hereditary complement factor I deficiency. , 1996, The Journal of clinical investigation.

[109]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.

[110]  C. Bell,et al.  Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy , 2007, Journal of Medical Genetics.

[111]  Dongsheng Duan,et al.  Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy , 2002, Nature Medicine.

[112]  Julie Donaghey,et al.  Deregulated Protein Kinase A Signaling and Myospryn Expression in Muscular Dystrophy* , 2008, Journal of Biological Chemistry.

[113]  N. Keep,et al.  The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. , 2000, Structure.

[114]  L. Truedsson,et al.  Complement factor I deficiency associated with recurrent infections, vasculitis and immune complex glomerulonephritis , 2005, Scandinavian journal of infectious diseases.

[115]  F. Muntoni,et al.  Large in-frame deletions of the rod-shaped domain of the dystrophin gene resulting in severe phenotype. , 2003, The Israel Medical Association journal : IMAJ.

[116]  Y. Berwald‐Netter,et al.  Dystrophin gene transcribed from different promoters in neuronal and glial cells , 1990, Nature.

[117]  C. Ponting,et al.  Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex , 2000, Current Biology.

[118]  A. Jauch,et al.  MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls , 2005, Neurogenetics.

[119]  K. Davies,et al.  Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with β-dystroglycan , 2007, The Journal of cell biology.

[120]  Christophe Béroud,et al.  Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.

[121]  L. Kunkel,et al.  Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. , 1990, The Journal of biological chemistry.

[122]  M. López-Trascasa,et al.  Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. , 2001, Archives of neurology.

[123]  H. Colten,et al.  Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. , 1984, The Journal of biological chemistry.

[124]  P. Barlow,et al.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. , 2010, Blood.

[125]  K. Campbell,et al.  Interactions of intermediate filament protein synemin with dystrophin and utrophin. , 2006, Biochemical and biophysical research communications.

[126]  Livija Medne,et al.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.

[127]  M. Taniike,et al.  Molecular study of duchenne and Becker muscular dystrophies in Japanese , 1991, Journal of Inherited Metabolic Disease.

[128]  K. Campbell Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage , 1995, Cell.

[129]  C. Carter Mendelian Inheritance in Man , 1967 .